Esophageal Cancer Clinical Trials & Research

Researchers at Memorial Sloan Kettering are studying new approaches to esophageal cancer, and we come closer to finding exciting solutions every day. One of the most important goals we have is to develop better treatments for people with esophageal cancer who are not helped by standard treatments.

We lead clinical trials to make current treatments better and to enhance the quality of life for people with esophageal cancer. Eligible patients may get experimental treatments before they are widely available elsewhere.

Memorial Sloan Kettering’s clinical trials for esophageal cancer are listed below. There may be other trials that are right for your cancer. Consult with your physician, who can ask if a trial is right for you.

and/or
27 Clinical Trials found
A Phase 1b Study of CHS-114 and Toripalimab in People With Advanced Digestive Cancers
Researchers are assessing different doses of CHS-114 when combined with toripalimab in people with advanced digestive cancers. The people in this study have digestive cancers that have metastasized (spread) or are inoperable (cannot be surgically removed). These cancers include:
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1b-2 Study of ZL-1310 in People With Gastroenteropancreatic Neuroendocrine Cancers
Researchers want to find the best dose of ZL-1310 to use in people with advanced digestive tumors. The people in this study have gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) that spread and keeps growing after treatment. These tumors include NEC of the esophagus, stomach, pancreas, gallbladder, or colon/rectum.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of AZD0901 and Rilvegostomig Plus Standard Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer
Researchers want to see if combining AZD0901 and rilvegostomig with standard chemotherapy works well in people with gastric or gastroesophageal junction (GEJ) cancer. GEJ cancer occurs where the esophagus joins the stomach.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 2 Study of Pembrolizumab Immunotherapy With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Researchers are assessing the use of multiple medications given before surgery to treat esophagogastric cancers. The people in this study have esophagus, stomach, or gastro-esophageal junction cancers that can be taken out (operable). In addition, their cancers make a protein called HER2.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 3 Study of AZD0901 Versus Standard Therapy to Treat Advanced Stomach or Gastroesophageal Junction Cancer With Claudin18.2
Researchers are comparing AZD0901 with standard treatments in people with advanced gastric cancer. The people in this study have cancer of the stomach or the junction between the esophagus and stomach (gastroesophageal junction). The people in this study have cancers that make a protein called Claudin18.2 (CLDN18.2).
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 3 Study of Trastuzumab Deruxtecan Plus Chemotherapy With or Without Pembrolizumab Versus Trastuzumab Plus Chemotherapy With or Without Pembrolizumab in People With Gastric or Gastroesophageal Junction Cancers
Researchers are comparing several combination drug treatments for people with cancer of the stomach or gastroesophageal junction (GEJ). The people in this study have gastric or GEJ cancer that metastasized (spread) or is inoperable (cannot be surgically removed). In addition, their tumors make a protein called HER2.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 3, Multicenter, Prospective Open-Label Study of the Diagnostic Performance of [18F]FAPI-74 PET/CT for the Detection of Metastatic Disease in Adults with Gastric or Esophageal Cancer (FAPI-GO)
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase I Study of TJ033721 Immunotherapy in People with Advanced Pancreatic or Esophagogastric Cancer
The purpose of this study is to find the highest dose of the investigational immunotherapy drug TJ033721 that can be given safely in people with advanced cancers of the pancreas, esophagus, stomach, or junction between the esophagus and stomach. TJ033721 is an antibody that binds to Claudin 18.2, a protein expressed on some cancers cells, and to 4-1BB, a protein found on immune cells. TJ033721 may strengthen the immune system's ability to fight cancer cells by activating a patient's own cells to destroy the tumor. It is given intravenously (by vein).
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Study of BNT329 in People With Solid Tumors
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Study of Cadonilimab Combined With Chemotherapy in People With Gastric or Gastroesophageal Junction Cancer
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau